Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

President Donald Trump has demanded major pharmaceutical companies cut U.S. drug prices within 60 days, threatening to deploy "every tool in our arsenal" if they fail to comply. This directive, following his revival of the "most favored nation" policy, intensifies government pressure on the pharmaceutical industry to align U.S. prices with lower international rates and provide immediate consumer relief, rejecting prior industry proposals as insufficient.

Analysis

The pharmaceutical sector faces significant and immediate regulatory pressure following President Trump's directive for 17 major drugmakers, including Eli Lilly, GSK, and Pfizer, to reduce U.S. drug prices within 60 days. This ultimatum represents a direct escalation of the administration's efforts, building on the revived "most favored nation" policy which aims to align domestic prices with the substantially lower rates in other developed nations. The President's explicit rejection of prior industry proposals as insufficient, coupled with the threat to deploy "every tool in our arsenal" and impose potential tariffs, introduces substantial uncertainty for revenue and margin forecasts. The strongly negative sentiment signal (-0.6 overall, -0.7 for named tickers) underscores the market's perception of this as a credible threat to the industry's highly profitable U.S. pricing structure, which, according to the Rand Corp., sees prices two to ten times higher than abroad.

Key Decisions for Investors

• Investors should immediately review their exposure to the named pharmaceutical companies (LLY, GSK, PFE, REGN, MRK, NVO) and the broader sector, as the threat of government-mandated price cuts introduces a significant headwind to future earnings.
• Monitor company and PhRMA lobbying group responses over the 60-day period, as their posture will be a key indicator of potential compliance, negotiation, or escalating conflict with the administration.
• Consider the risk of margin compression and potential tariffs on imported pharmaceuticals, which may warrant adopting hedging strategies or re-evaluating positions in companies with high revenue concentration in the U.S. market.